On August 26, 2026, stock prices for Chinese biotech companies listed in Hong Kong surged following Moderna’s successful cancer vaccine trial results, which demonstrated a reduction in melanoma recurrence. Prominent firms like Jiangsu Hengrui Pharmaceuticals and CK Life Sciences are advancing similar vaccine programs, with over 100 cancer vaccine projects reportedly under development in China. Experts highlight the challenge of replicating Moderna’s success across different tumor types and the need to produce personalized vaccines efficiently and affordably to tap into the significant market for cancer treatments, considering China’s high cancer mortality rate.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.indexbox.io/blog/chinese-biotech-stocks-surge-on-modernas-cancer-vaccine-breakthrough/
